Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Á¶·çÁõ ȯÀÚ Ä¡·á¿¡¼­ Sertraline ÇÊ¿ä½Ã ÀÚ°¡º¹¿ë¿ä¹ý: ´Ü±â ÃßÀû °á°ú Self Therapy with Sertraline as Needed Basis in Treatment of Premature Ejaculation: Short Term Follow-up Results

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 9È£ p.916 ~ 920
ÃÖ¼øö, ÀÓ´ëÁ¤, ±¹¸íö, ±è¿µ°É,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖ¼øö (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

ÀÓ´ëÁ¤ (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±¹¸íö (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±è¿µ°É (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Á¶·çÁõÀº ¿¬·É¿¡ °ü°è¾øÀÌ ¾à 30%ÀÇ ³²¼º¿¡°Ô ³ªÅ¸³ª´Â °¡Àå ÈçÇÑ ¼º±â´É ÀÌ»óÀÌ´Ù. ±×
·¯³ª ÈçÇÑ ÁúȯÀÓ¿¡µµ ºÒ±¸ÇÏ°í ÇöÀç±îÁö Á¶·çÁõÀÇ Á¤ÀÇ, ¿øÀÎ, Ä¡·á µî¿¡ ´ëÇÑ Á¤¼³Àº ¾ø´Â
½ÇÁ¤ÀÌ´Ù. Á¶·çÁõÀº ÀüÅëÀûÀ¸·Î Á¤½ÅÀû ¿øÀο¡ ÀÇÇÑ º´À¸·Î ¹Ï¾îÁö°í ÀÖ¾î Çൿ¿ä¹ý µîÀÇ
Á¤½Å¿ä¹ýÀÌ ¿ì¼±ÀûÀ¸·Î ½ÃÇàµÇ¾î ¿Ô´Ù. ±×·¯³ª ÀÌ Ä¡·á¹ýÀº Ãʱ⿡´Â 60-95%ÀÇ ³ôÀº ¼º°ø
·üÀ» º¸À̳ª ±× È¿°ú°¡ Áö¼ÓÀûÀÌÁö ¸øÇØ Ä¡·á ÈÄ 3³â¿¡´Â ¼º°ø·üÀÌ 25%¿¡ ºÒ°úÇÏ´Ù°í ÇÑ
´Ù. ´õ¿íÀÌ ¿ì¸® ³ª¶ó¿Í °°Àº ¹®È­Àû ¹è°æ¿¡¼­´Â ¼º°ø·üÀÌ ÀÌ¿¡µµ »ó´çÈ÷ ¸ø ¹ÌÄ¡¸®¶ó ¿¹»ó
µÈ´Ù
ÃÖ±ÙÀÇ ¿©·¯ º¸°í¸¦ ÅëÇØ selective serotonin reuptake inhibitors(SSRIs)°¡ Á¶·çÁõÀÇ Ä¡·á
¿¡ È¿°úÀûÀ̶ó´Â »ç½ÇÀÌ ¹àÇôÁø ¹Ù ÀÖ´Ù. ±×·¯³ª SSRIsÀÇ Á¶·çÁõ Ä¡·áÈ¿°ú´Â ¾à Åõ¿©¸¦ Áß
´ÜÇÏ¸é °ÅÀÇ ´ëºÎºÐ ¼Ò½ÇµÇ¹Ç·Î Ä¡·áÈ¿°ú¸¦ À¯ÁöÇϱâ À§Çؼ­´Â Àå±â°£ÀÇ ¾à¹°º¹¿ëÀÌ ÇÊ¿äÇÏ
´Ù. ¾àÁ¦ÀÇ Àå±âº¹¿ëÀº ¸¹Àº ºñ¿ë°ú ºÎÀÛ¿ëÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ´Ù ±×·¯¹Ç·Î ÇÊ¿äÇÒ ¶§¸¸ º¹¿ëÄÉ
ÇÏ´Â ¹æ¹ýÀÌ È¿°úÀûÀ̶ó¸é ºñ¿ë, ¾ÈÀü¼º, °£ÆíÇÔ µîÀÇ Ãø¸é¿¡¼­ °¡Àå ÀÌ»óÀûÀÎ Ä¡·á¹ýÀ̶ó
ÇÒ ¼ö ÀÖ´Ù. ÃÖ±Ù SSRIs¸¦ ÇÊ¿äÇÒ ¶§¸¸ º¹¿ëÄÉ ÇÏ´Â Ä¡·á¹ýÀ» ½ÃµµÇÑ ¸î¸î º¸°íµéÀÌ ÀÖ¾ú
À¸³ª ´ë»ó±ºÀÇ ¼ö°¡ Àû°Å³ª ±× °á°ú°¡ °´°üÀûÀÌÁö ¾Ê¾Ò´Ù.
ÀÌ¿¡ ÀúÀÚµéÀº ¹ß±âºÎÀüÁõ ȯÀÚÀÇ ÀÚ°¡ÁÖ»ç¿ä¹ýó·³ SSRIs°¡ Á¶·çÁõ ȯÀÚÀÇ ÀÚ°¡º¹¿ë¿ä
¹ýÀ¸·Î È¿°úÀûÀÌ¸ç ¾ÈÀüÇÏ°Ô »ç¿ëµÉ ¼ö ÀÖ´ÂÁöÃâ ½ÃÇèÇϱâ À§ÇØ º» ¿¬±¸¿¡ Âø¼öÇÏ¿´´Ù. º»
¿¬±¸ÀÇ Ä¡·á¾àÁ¦·Î sertralineÀ» ¼±ÅÃÇÑ ÀÌÀ¯´Â ¿©·¯ SSRI Áß ¼¼·ÎÅä´Ñ ÀçÈí¼ö¸¦ ¸Å¿ì ¼±ÅÃ
ÀûÀ¸·Î Â÷´ÜÇÏ´Â À¯·ÂÇÑ ¾àÁ¦À̸ç, ¿ë·® Áõ°¡¿¡µµ ºÐº¹ÇÒ ÇÊ¿ä°¡ ¾ø´Ù´Â ÀåÁ¡ÀÌ Àֱ⠶§¹®
À̾ú´Ù ÇÊ¿ä½Ã ÀÚ°¡º¹¿ë ½Ã°£À» ¿ÀÈÄ 5½Ã·Î Á¤ÇÑ °ÍÀº ´ëºÎºÐÀÇ Á÷Àå³²¼ºµéÀÌ ÇÏ·çÀÇ ÀÏ°ú
¸¦ Á¤¸®ÇÏ°í Àú³á ÀÏÁ¤Ç¥¸¦ ºñ·ÔÇÑ ±×³¯ÀÇ ¼º»ýÈ° ¿©ºÎ¸¦ ¿¹»óÇϱâ ÀûÀýÇÑ ½Ã°£À̸ç, ÀϹÝ
ÀûÀÎ ¼º»ýÈ° ½Ã°£ÀÎ ¿ÀÈÄ 11½Ã ÀüÈÄ¿¡ sertralineÀÌ Ç÷Áß ÃÖ°í³óµµ¿¡ À̸£±â ¶§¹®ÀÌ´Ù
#ÃÊ·Ï#
Purpose: Pharmacotherapy using selective serotonin reuptake inhibitors(SSRls) for men
with primary premature ejaculation(PE) is promising. Specially, a strategy taking a pill
'as needed' may offer an attractive option. To investigate the possibility of self therapy,
patients treated for PE with sertraline 'as needed' basis were evaluated.
Materials and Methods: Since 1996 we have treated 24 males with sertraline 'as
needed' basis for primary PE. We chose sertraline among SSRIs because alarge dose
need not to be divided and peak plasma levels occurring 4-8 hours after oral
administration makes 5 p.m. suitable for the time of administration. Five p.m. is the
time the ordinary men usually fix their evening schedule including intercourses. Each
patient was started on 50§· qd for 2 weeks and then the dose was adjusted to 50 or
100§· only on the day of intercourse.
Results: After 6 weeks, 18 men continued to take medication and 6 had dropped out.
Of 18 men, mean ejaculation latency were 23¡¾19sec before treatment, 5.9¡¾4.2min after
2wks 50§· qd, 5.1¡¾3.8min after 2wks 50/100§· pm and 4.5¡¾2.7min after 4wks 50/100§·
prn and mean sexual satisfaction scores ('5'=extremely satisfied, '0'=extremely
unsatisfied) of men were 0.8¡¾0.8 before treatment, 3.8¡¾1.2 after 2wks 50§· qd, 3.4¡¾1.0
after 2wks 50/100§· pm and 3.2¡¾0.7 after 4wks 50/100§· pm. And mean sexual
satisfaction scores of partners were 1.1¡¾0.7 before treatment, 3.2¡¾1.6 after 2wks 50§·
qd,3.1¡¾1.4 after 2wks 50/100§· pm and 3.3¡¾1.2 after 4wks 50/100§· pm. Side effects
were intermittent excessive delay in 1 patient, fatigue in 2 patients, numbness in 1
patient.
Conclusions: If our results were supported by additional clinical long term study, self
therapy with sertraline given pm at 5 pm in treatment of PE could be as attractive as
self injection therapy in the treatment of erectile dysfunction.

Å°¿öµå

Premature ejaculation; Setraline; Self therapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS